文献速递糖尿病

闭环胰岛素输注与传感器增强泵疗法在老年1型糖尿病患者中的比较(ORACL):一项随机交叉试验

Closed-Loop Insulin Delivery Versus Sensor-Augmented Pump Therapy in Older Adults With Type 1 Diabetes (ORACL): A Randomized, Crossover Trial.
PubMed 文献 · Diabetes Care · 2022-01-01

该开放标签、随机(1:1)、交叉试验比较闭环与传感器增强泵疗法各4个月在≥60岁、1型糖尿病病程≥10年且使用胰岛素泵的老年患者中的疗效与安全性。30例参与者平均年龄67岁,闭环阶段平均TIR为75.2% vs 传感器增强泵阶段69.0%(差值6.2个百分点,95%CI 4.4至8.0;P<0.0001),所有预设CGM指标均支持闭环,夜间获益最大。闭环降低24小时CGM时间<3.9 mmol/L 0.5个百分点(95%CI 0.3至1.1;P=0.0005),夜间降低0.8个百分点(0.4至1.1;P<0.0001)。HbA1c两组无显著差异(P=0.13)。闭环阶段发生3例严重低血糖,传感器增强泵阶段2例,均无需住院;传感器增强泵阶段发生1例糖尿病酮症酸中毒,闭环阶段无严重不良事件。

要点

  • 闭环阶段平均TIR为75.2%,传感器增强泵阶段为69.0%,差值6.2个百分点(95%CI 4.4至8.0;P<0.0001)。
  • 闭环降低24小时CGM时间<3.9 mmol/L 0.5个百分点(95%CI 0.3至1.1;P=0.0005),夜间降低0.8个百分点(0.4至1.1;P<0.0001)。
  • HbA1c两组无显著差异(P=0.13);闭环阶段3例严重低血糖,传感器增强泵阶段2例,均无需住院。

核心结论

  • 闭环疗法是老年长病程1型糖尿病患者的有效治疗选择,未发现安全问题。
  • 与传感器增强泵疗法相比,闭环阶段TIR更高且低于范围时间更少,尤其减少夜间低血糖时间。

研究设计与样本

  • 开放标签、随机(1:1)、交叉试验,比较4个月闭环与传感器增强泵疗法。
  • 纳入年龄≥60岁、1型糖尿病病程≥10年、使用胰岛素泵的成人;30例参与者随机分配(每个序列n=15),全部完成试验。
  • 主要结局为连续血糖监测(CGM)目标范围内时间(TIR;3.9-10.0 mmol/L)。

主要发现

  • 闭环阶段平均TIR为75.2%(SD 6.3),传感器增强泵阶段为69.0%(SD 9.1),差值6.2个百分点(95%CI 4.4至8.0;P<0.0001)。
  • 所有预设CGM指标均支持闭环优于传感器增强泵,夜间获益最大。
  • 闭环降低24小时CGM时间<3.9 mmol/L 0.5个百分点(95%CI 0.3至1.1;P=0.0005),夜间降低0.8个百分点(95%CI 0.4至1.1;P<0.0001)。
  • HbA1c闭环阶段7.3%(IQR 7.1-7.5;56 mmol/mol [54-59])vs 传感器增强泵阶段7.5%(IQR 7.1-7.9;59 mmol/mol [54-62]),无显著差异(P=0.13)。
  • 闭环阶段发生3例严重低血糖,传感器增强泵阶段2例,均无需住院;传感器增强泵阶段发生1例糖尿病酮症酸中毒,闭环阶段无严重不良事件。

关键数值与推荐

  • 主要结局TIR目标范围3.9-10.0 mmol/L。
  • 闭环阶段TIR 75.2% vs 传感器增强泵阶段69.0%,差值6.2个百分点(95%CI 4.4至8.0;P<0.0001)。
  • 闭环降低24小时CGM时间<3.9 mmol/L 0.5个百分点(95%CI 0.3至1.1;P=0.0005),夜间降低0.8个百分点(95%CI 0.4至1.1;P<0.0001)。
  • HbA1c闭环阶段7.3%(IQR 7.1-7.5;56 mmol/mol [54-59])vs 传感器增强泵阶段7.5%(IQR 7.1-7.9;59 mmol/mol [54-62]),P=0.13。

临床怎么用

  • 原文未据此给出推荐。
  • 作者结论认为闭环疗法是老年长病程1型糖尿病患者的有效治疗选择,未发现安全问题。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the efficacy and safety of closed-loop insulin delivery compared with sensor-augmented pump therapy among older adults with type 1 diabetes. RESEARCH DESIGN AND METHODS: This open-label, randomized (1:1), crossover trial compared 4 months of closed-loop versus sensor-augmented pump therapy. Eligible adults were aged ≥60 years, with type 1 diabetes (duration ≥10 years), using an insulin pump. The primary outcome was continuous glucose monitoring (CGM) time in range (TIR; 3.9-10.0 mmol/L). RESULTS: There were 30 participants (mean age 67 [SD 5] years), with median type 1 diabetes duration of 38 years (interquartile range [IQR] 20-47), randomized (n = 15 to each sequence); all completed the trial. The mean TIR was 75.2% (SD 6.3) during the closed-loop stage and 69.0% (9.1) during the sensor-augmented pump stage (difference of 6.2 percentage points [95% CI 4.4 to 8.0]; P < 0.0001). All prespecified CGM metrics favored closed loop over the sensor-augmented pump; benefits were greatest overnight. Closed loop reduced CGM time <3.9 mmol/L during 24 h/day by 0.5 percentage points (95% CI 0.3 to 1.1; P = 0.0005) and overnight by 0.8 percentage points (0.4 to 1.1; P < 0.0001) compared with sensor-augmented pump. There was no significant difference in HbA1c between closed-loop versus sensor-augmented pump stages (7.3% [IQR, 7.1-7.5] (56 mmol/mol [54-59]) vs. 7.5% [7.1-7.9] (59 mmol/mol [54-62]), respectively; P = 0.13). Three severe hypoglycemia events occurred during the closed-loop stage and two occurred during the sensor-augmented pump stage; no hypoglycemic events required hospitalization. One episode of diabetic ketoacidosis occurred during the sensor-augmented pump stage; no serious adverse events occurred during the closed-loop stage. CONCLUSIONS: Closed-loop therapy is an effective treatment option for older adults with long-duration type 1 diabetes, and no safety issues were identified. These older adults had higher TIR accompanied by less time below range during closed loop than during sensor-augmented pump therapy. Of particular clinical importance, closed loop reduced the time spent in hypoglycemic range overnight.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. McAuley SA, Trawley S, Vogrin S, et al. Closed-Loop Insulin Delivery Versus Sensor-Augmented Pump Therapy in Older Adults With Type 1 Diabetes (ORACL): A Randomized, Crossover Trial. Diabetes Care. 2022. PMID: 34844995. doi:10.2337/dc21-1667

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。